SCHEMBL14486608

SCHEMBL14486608

COc1cc(SCc2ccc(F)cc2)cnc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.45
▸ POLB P06746 2/20 0.45
▸ HTT P42858 1/20 0.43
▸ CKS1B P61024 1/20 0.42
▸ SKP2 Q13309 1/20 0.42
▸ MAOA P21397 3/20 0.41
▸ MAOB P27338 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ GPBAR1 Q8TDU6 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14486022 0.89 MAPT (0.42) MAPTHTTSMN1; SMN2NPC1RAB9A
SCHEMBL14486725 0.87 MEN1 (0.54) MAPTHTTMAOAMAOBSMN1; SMN2
SCHEMBL14486622 0.87 GCK (0.46) MAPTHTTSMN1; SMN2NPC1RAB9A
SCHEMBL31294237 0.82 APP (0.49) MAPTPOLBMAOAMAOBSMN1; SMN2
SCHEMBL14486338 0.81 DAO (0.44) MAPTPOLBSMN1; SMN2NPC1RAB9A
SCHEMBL14485742 0.80 L3MBTL1 (0.48) MAPTHTTMAOBSMN1; SMN2NPC1
SCHEMBL31294328 0.79 APP (0.49) MAPTPOLBCKS1BSKP2MAOA
SCHEMBL14485803 0.79 MAPT (0.44) MAPTHTTSMN1; SMN2RAB9AL3MBTL1
SCHEMBL14486647 0.78 RAB9A (0.47) MAPTPOLBHTTSMN1; SMN2RAB9A
SCHEMBL14486615 0.76 PIK3CG (0.44) MAPTHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2729449-B1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICALS CO (JP) 2017-10-18 — — EP disclosed
EP-2729449-B1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICALS CO (JP) 2017-10-18 — — EP disclosed
US-9180122-B2 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-9180122-B2 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-9180122-B2 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 — — US disclosed
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 — — US disclosed
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 — — US disclosed
EP-2729449-A1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN Takeda Pharmaceutical Company Limited (JP) 2014-05-14 — — EP disclosed
WO-2013004996-A1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID DAO, DDO, HAO1 MAPT 1990/4885POLB 2057/4885HTT 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback